Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

BigSqueezeComing Jun. 19 at 3:56 AM

$LXRX On Friday, we’ll either break out above $1 or continue trading sideways near current levels. Either way, I’m staying long. Not selling until $12.

0 · Reply

popsallen Jun. 19 at 2:28 AM

$LXRX could be interesting friday PM! Same with GURE - it had some great movement AH as well!

0 · Reply

Bgf1992 Jun. 18 at 10:34 PM

$LXRX markets closed tomorrow. Big push on Friday?

1 · Reply

BigSqueezeComing Jun. 18 at 9:44 PM

$LXRX we had a hard time crossing .75 without vol.

0 · Reply

Oxs Jun. 18 at 8:15 PM

$LXRX This Sunday at the ADA’s 85th Scientific Sessions in Chicago, both Novo Nordisk and Lexicon Pharmaceuticals will be showcasing their work. Novo Nordisk is presenting 29 abstracts, which include new data on semaglutide and CagriSema. On the other hand, Lexicon has several presentations scheduled for Sunday, June 22, likely focusing on related research. Although LX9851 is still in the preclinical stage, its mechanism and therapeutic goals align closely with the combination obesity treatments Novo is highlighting at ADA. Novo Nordisk is all in, if we see positive results. Novo Nordisk and Eli Lilly, have been competing for over 100 years. Novo Nordisk ain´t losing this fight in this category, which been going on for over 20 years.

1 · Reply

SPARTANWHITE22 Jun. 18 at 7:35 PM

$LXRX If you are selling for a few dollars this day...stop posting you are bullish...thanks....

0 · Reply

epk1970 Jun. 18 at 6:05 PM

$LXRX

0 · Reply

Michaeljoel Jun. 18 at 5:43 PM

$LXRX

0 · Reply

epk1970 Jun. 18 at 5:41 PM

$LXRX Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) https://finance.yahoo.com/news/lexicon-present-data-85th-scientific-123000744.html Could be some good announcements coming soon, or at least some positive information on progress...

0 · Reply

Marta22 Jun. 18 at 5:30 PM

$LXRX 4. Complementarity with existing therapies Integrated approach: Sotagliflozin does not work alone to treat type 1 diabetes, but it can be used in combination with other therapies, including insulin, in a way that helps control glucose levels without the risk of hypoglycemia. This is consistent with current FDA recommendations, which favor combinations of medications that allow patients to better manage their glucose levels with minimal risk of hypoglycemia. 5. FDA cooperation and meeting safety standards Lexicon is actively working with the FDA to meet all safety standards and provide the necessary clinical data to prove that sotagliflozin is safe and effective for long-term use. Reducing the risk of hypoglycemia is a key part of this effort.

1 · Reply

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 20 days ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 4 weeks ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 5 weeks ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 5 weeks ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 6 weeks ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 6 weeks ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 7 weeks ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 2 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 2 months ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

Mar 28, 2025, 7:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 7, 2025, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 6, 2025, 10:52 PM EST - 3 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:00 PM EST - 3 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 4:15 PM EST - 3 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mar 3, 2025, 7:00 AM EST - 3 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Mar 2, 2025, 4:13 PM EST - 3 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Feb 18, 2025, 8:00 AM EST - 4 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Jan 21, 2025, 8:00 AM EST - 5 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Jan 2, 2025, 8:00 AM EST - 5 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Dec 20, 2024, 4:46 PM EST - 6 months ago

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024, 4:30 PM EST - 6 months ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Nov 26, 2024, 8:00 AM EST - 7 months ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Nov 25, 2024, 4:15 PM EST - 7 months ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Nov 22, 2024, 7:47 AM EST - 7 months ago

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Nov 22, 2024, 7:32 AM EST - 7 months ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 20, 2024, 4:05 PM EST - 7 months ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Nov 12, 2024, 8:39 PM EST - 7 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 7 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 8:00 AM EST - 8 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 8 months ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 6:54 PM EDT - 8 months ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 4:54 PM EDT - 8 months ago

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Oct 16, 2024, 4:35 PM EDT - 8 months ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Oct 16, 2024, 4:34 PM EDT - 8 months ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

VTRS

Sep 27, 2024, 8:00 AM EDT - 9 months ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Sep 16, 2024, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Sep 10, 2024, 8:00 AM EDT - 10 months ago

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Sep 3, 2024, 4:00 PM EDT - 10 months ago

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 13, 2024, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Aug 7, 2024, 8:00 AM EDT - 11 months ago

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Aug 3, 2024, 6:29 AM EDT - 11 months ago

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 1, 2024, 11:00 PM EDT - 11 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 8:00 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Jul 8, 2024, 9:15 AM EDT - 1 year ago

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

May 29, 2024, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades

BigSqueezeComing Jun. 19 at 3:56 AM

$LXRX On Friday, we’ll either break out above $1 or continue trading sideways near current levels. Either way, I’m staying long. Not selling until $12.

0 · Reply

popsallen Jun. 19 at 2:28 AM

$LXRX could be interesting friday PM! Same with GURE - it had some great movement AH as well!

0 · Reply

Bgf1992 Jun. 18 at 10:34 PM

$LXRX markets closed tomorrow. Big push on Friday?

1 · Reply

BigSqueezeComing Jun. 18 at 9:44 PM

$LXRX we had a hard time crossing .75 without vol.

0 · Reply

Oxs Jun. 18 at 8:15 PM

1 · Reply

SPARTANWHITE22 Jun. 18 at 7:35 PM

$LXRX If you are selling for a few dollars this day...stop posting you are bullish...thanks....

0 · Reply

epk1970 Jun. 18 at 6:05 PM

$LXRX

0 · Reply

Michaeljoel Jun. 18 at 5:43 PM

$LXRX

0 · Reply

epk1970 Jun. 18 at 5:41 PM

0 · Reply

Marta22 Jun. 18 at 5:30 PM

1 · Reply

Marta22 Jun. 18 at 5:29 PM

$LXRX 3. Individualized approach to the patient. Different levels of renal function: Sotagliflozin is also being studied in the context of different levels of renal function, which is important given that patients with impaired renal function may be at higher risk of hypoglycemia. With this patient group, Lexicon is working to optimize dosing and monitor safety, especially in those with lower eGFR. Reduced risk of hypoglycemia: Further studies are underway to confirm that sotagliflozin can help patients with type 1 diabetes who have difficulty controlling glucose without putting them at risk for dangerous hypoglycemia, which meets the FDA’s requirements to minimize the risk of this complication.

0 · Reply

Marta22 Jun. 18 at 5:28 PM

$LXRX Advantages: Unlike traditional type 1 diabetes medications that can increase the risk of hypoglycemia (e.g. insulin), sotagliflozin helps stabilize glucose levels in a way that does not lead to dangerous drops in glucose levels. 2. Clinical Trials and Safety Lexicon bases its approach on robust clinical trials that aim to prove that sotagliflozin reduces the number of hypoglycemia episodes in patients with type 1 diabetes, particularly in those with varying degrees of kidney function (eGFR). These studies are crucial to meeting FDA requirements for safety and effectiveness. The presentation of preliminary results at the ADA conference (including the one on hypoglycemia) is an important step in building evidence of sotagliflozin’s efficacy and safety, which may support further progress in the FDA approval process.

0 · Reply

Marta22 Jun. 18 at 5:27 PM

$LXRX LXRX is focusing on sotagliflozin as a key element of its approach to addressing the risk of hypoglycemia, particularly in the context of type 1 diabetes. The FDA, as part of its guidance, places great emphasis on patient safety, especially in terms of preventing hypoglycemia – a serious health risk that can lead to uncontrolled episodes and even life-threatening situations. Here are the key elements of Lexicon’s strategy for addressing the FDA’s recommendations: 1. Sotagliflozin as a dual-functional SGLT1 and SGLT2 inhibitor Mechanism of action: Sotagliflozin works by inhibiting two sodium-glucose transporters (SGLT1 and SGLT2). SGLT2 is responsible for glucose reabsorption in the kidneys, and SGLT1 is responsible for glucose transport in the gastrointestinal tract. Thanks to this, sotagliflozin has the ability to lower blood glucose levels without increasing the risk of hypoglycemia, which may occur with other insulin therapies that lower glucose levels more strongly.

0 · Reply

macrossluvsrobotech Jun. 18 at 5:06 PM

$LXRX That Novo Deal was likely struck because of these presentations. The 'new' thing here is this event venue at which they have never prsented WITH THIS SPECIFIC DATA OR INFORMATION, updated the latest on LXRX pipeline results and studies. A pattern I've noticed is after these presentations it seems there is hire pur hase volume, in my view for obvious reasons as per financially well endowed attendees, hedge funds and majors in the field . https://investors.lexpharma.com/news-releases/news-release-details/lexicon-present-data-85th-scientific-sessions-american-diabetes/ Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | June 18, 2025

0 · Reply

Beebomb Jun. 18 at 4:51 PM

$LXRX I would not get my knickers in a knot over the ADA presentations coming up. There seems to be nothing new. Correct me if that is mistaken.

1 · Reply

macrossluvsrobotech Jun. 18 at 4:27 PM

$LXRX During the 85th Scientific Sessions, Lexicon also will present topline data from its PROGRESS Phase 2b study evaluating pilavapadin in adults with diabetic peripheral neuropathic pain. Presentation details: “Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)--Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study” -- Sunday, June 22, 12:30-1:30 p.m. CT, Board No. 1876, Poster Hall F1 Lexicon Pharmaceuticals, Inc. today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association. At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin in adults with diabetic peripheral neuropathic pain. Held June 20–23, 2025 at the McCormick Place Convention Center in Chicago, Illinois.

1 · Reply

Jbjb90 Jun. 18 at 4:19 PM

$LXRX They haven’t announced anything big then heading into the end of the time to become compliant they pull out the big guns and drop something major Sunday, look out next week, lets fucking go 🤞

0 · Reply

Jbjb90 Jun. 18 at 4:04 PM

$LXRX https://www.stocktitan.net/news/LXRX/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-6y3brdoy049n.html $ELTP https://www.stocktitan.net/news/ELTP/elite-pharmaceuticals-reports-positive-results-from-a-pivotal-d87ba6cvnnsk.html

0 · Reply

Lagoule Jun. 18 at 3:47 PM

$LXRX Institutional Ownership! 🧨🚀🔥📈💎🙌💎

0 · Reply

BigSqueezeComing Jun. 18 at 3:42 PM

$LXRX Next stop .75 then .78

0 · Reply

larsson13 Jun. 18 at 3:30 PM

$LXRX eerily quiet on here tday...

1 · Reply

zoiecardenas Jun. 18 at 2:43 PM

$LXRX

1 · Reply

Market Cap	260.49M
Revenue (ttm)	31.08M
Net Income (ttm)	-200.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-644.79%
Debt to Equity Ratio	0.82

Volume	3,610,900
Avg Vol	5,079,668
Day's Range	N/A - N/A
Shares Out	361.49M
Stochastic %K	69%
Beta	1.00
Analysts	Sell
Price Target	$2.58